{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T03:20:39Z","timestamp":1783480839369,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,9,19]],"date-time":"2007-09-19T00:00:00Z","timestamp":1190160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2003<\/jats:bold> For patients with well\u2010differentiated thyroid carcinoma (WDTC), the gonadal effects of radioactive iodine (RAI) therapy is an important consideration.<\/jats:p><jats:p><jats:bold>Objective and methods\u2003<\/jats:bold> We systematically reviewed the controlled studies examining the gonadal effects of RAI therapy in male WDTC survivors. We searched in nine electronic databases. All abstracts and papers were independently reviewed by two reviewers.<\/jats:p><jats:p><jats:bold>Results\u2003<\/jats:bold> After reviewing 334 abstracts and 59 full\u2010text papers, seven papers were included. In longitudinal studies examining the effect of single primary RAI dose activities of\u00a0\u2264\u00a0150\u00a0mCi, serum FSH and LH rose between months 2 and 6, with normalization by 18\u00a0months; serum testosterone did not significantly decrease. In one study, 18\u00a0months after RAI, the rates of elevated serum FSH were: 27% for 351\u2013594\u00a0mCi and 81% for\u00a0&gt;\u00a0594\u00a0mCi. Cumulative RAI dose correlated with FSH measurements at long\u2010term follow\u2010up. In one study, approximately one in eight men experienced oligospermia 1\u00a0year after RAI therapy. Rates of infertility, pregnancy loss and offspring congenital malformation were not elevated, but studies were limited by small size and self\u2010reported outcomes.<\/jats:p><jats:p><jats:bold>Conclusions\u2003<\/jats:bold> Abnormalities in testicular function are common within several months of a single therapeutic dose of RAI for WDTC. Biochemical abnormalities usually resolve within 18\u00a0months after administration of a single activity of &lt;\u00a0150\u00a0mCi of RAI. The risk of persistent gonadal dysfunction is increased after repeated or high cumulative RAI activities. Controlled, prospective studies, with long\u2010term follow\u2010up, examining male gonadal and offspring effects of RAI therapy are needed.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2007.03081.x","type":"journal-article","created":{"date-parts":[[2007,9,22]],"date-time":"2007-09-22T01:54:04Z","timestamp":1190426044000},"page":"610-617","source":"Crossref","is-referenced-by-count":60,"title":["A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors"],"prefix":"10.1111","volume":"68","author":[{"given":"Anna M.","family":"Sawka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Lea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bandar","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Straus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Brierley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amiram","family":"Gafni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,9,19]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Canadian Cancer Society National Cancer Institute of Canada Statistics Canada & Public Health Agency of Canada.Canadian Cancer Statistics 2005. Available at:http:\/\/www.cancer.ca\u00a0[accessed 2 August 2005]."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-1-20"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otohns.2006.01.029"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.1229"},{"key":"e_1_2_6_6_2","first-page":"241","article-title":"Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2512 consecutive patients during 1940 through 2000","volume":"113","author":"Hay I.D.","year":"2002","journal-title":"Transactions of the American Clinical Climatological Association"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.109"},{"key":"e_1_2_6_8_2","unstructured":"National Cancer Institute. (2006)Thyroid Cancer (PDQ): Treatment. Available at:http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/thyroid\/healthprofessional\/allpages\u00a0[accessed 23 July 2006]."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02158"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.7.3.202"},{"key":"e_1_2_6_11_2","unstructured":"British Thyroid Association & Royal College of Physicians. (2002)Guidelines for the Management of Thyroid Cancer in Adults. Available at:http:\/\/www.british\u2010thyroid\u2010association.org\u00a0[accessed 23 July 2006]."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031167"},{"key":"e_1_2_6_13_2","first-page":"1716","article-title":"Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer","volume":"40","author":"Ceccarelli C.","year":"1999","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.t01-1-01545.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345187"},{"key":"e_1_2_6_16_2","unstructured":"Altman D.G. Machin D. Bryant T.N.&Gardner M.J.(2000)Stat\u00eest\u00eecs with confidence 2nd edn. BMJ Books London."},{"key":"e_1_2_6_17_2","first-page":"1418","article-title":"Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine","volume":"35","author":"Pacini F.","year":"1994","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050535"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.667"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841867209130760"},{"key":"e_1_2_6_21_2","first-page":"52","article-title":"Gonadal function in patients with differentiated thyroid cancer treated with 131, I","volume":"7","author":"Esfahani A.F.","year":"2004","journal-title":"Hellenic Journal of Nuclear Medicine"},{"key":"e_1_2_6_22_2","first-page":"460","article-title":"Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer","volume":"17","author":"Sarkar S.D.","year":"1976","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_23_2","first-page":"669","article-title":"Differentiated thyroid carcinoma in children and adolescents: a 37\u2010year experience in 85 patients","volume":"38","author":"Dottorini M.E.","year":"1997","journal-title":"Journal of Nuclear Medicine"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1983.tb02876.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-10-9-1007"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1651"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2007.03081.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2007.03081.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:41:53Z","timestamp":1697233313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2007.03081.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,19]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["10.1111\/j.1365-2265.2007.03081.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03081.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,19]]}}}